Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced HER2+Breast Cancer × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 421 Breast Neoplasms 264 Neoplasms 254 Colorectal Neoplasms 187 Neoplasm Metastasis 161 Prostatic Neoplasms 153 Ovarian Neoplasms 153 Multiple Myeloma 140 Lung Neoplasms 128 Melanoma 126 Recurrence 122 Stomach Neoplasms 105 Squamous Cell Carcinoma of Head and Neck 102 Endometrial Neoplasms 101 Pancreatic Neoplasms 94 Leukemia, Myeloid, Acute 83 Leukemia, Lymphocytic, Chronic, B-Cell 82 Triple Negative Breast Neoplasms 81 Small Cell Lung Carcinoma 76 Lymphoma, Non-Hodgkin 73 Lymphoma, Follicular 73 Urinary Bladder Neoplasms 69 Lymphoma, Large B-Cell, Diffuse 69 Carcinoma, Hepatocellular 66 Carcinoma, Renal Cell 64 Uterine Cervical Neoplasms 58 Head and Neck Neoplasms 55 Advanced Solid Tumors 55 Parkinson Disease 4, Autosomal Dominant Lewy Body 53 Lymphoma 53

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡